Gyre Therapeutics (GYRE) Raw Materials (2022 - 2026)

Gyre Therapeutics (GYRE) has reported Raw Materials for 5 consecutive years, with $1.2 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Raw Materials changed 0.43% year-over-year to $1.2 million; the TTM figure through Mar 2026 stood at $1.2 million (changed 0.43% YoY), while the FY2025 annual figure was $970000.0, up 22.17% from the prior year.
• Raw Materials rose to $1.2 million in Q1 2026 per GYRE's latest filing, from $970000.0 in the prior quarter.
• Across five years, Raw Materials topped out at $1.2 million in Q2 2025 and bottomed at $724000.0 in Q1 2024.
• Historically, Raw Materials has averaged $1.0 million across 5 years, with a median of $1.1 million in 2022.
• Annual changes were most pronounced in 2024 — Raw Materials slipped 13.6% — and 2025, when it jumped 61.46%.
• Gyre Therapeutics' Raw Materials stood at $1.1 million in 2022, then declined by 12.97% to $919000.0 in 2023, then declined by 13.6% to $794000.0 in 2024, then increased by 22.17% to $970000.0 in 2025, then grew by 21.03% to $1.2 million in 2026.
• Business Quant data shows GYRE's Raw Materials at $1.2 million in Q1 2026, $970000.0 in Q4 2025, and $1.1 million in Q3 2025.